Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib
Zilurgisertib exposure was unchanged with mild renal or moderate hepatic impairment, but increased by 30%-70% with moderate or more severe renal impairment and by 25% with severe hepatic impairment. These findings, alongside the therapeutic index, to be defined by the ongoing pivotal FOP trial (NCT05090891), will guide dosing in these populations.
Authors
- Jay Getsy
- Yan‐ou Yang (ORCID: https://orcid.org/0009-0005-4869-9492)
- Kevin Rockich
- Phillip Wang (ORCID: https://orcid.org/0009-0007-0400-514X)
- Xiang Liu (ORCID: https://orcid.org/0009-0004-0904-8067)
- Yunlan Fang
Institutions
- Incyte (United States) (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1002/bcp.70372
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Incyte